| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 79,9 M € | +1.7% | 78,6 M € | -3.6% | 81,5 M € | +7.6% | 75,8 M € | +3.8% | 73,0 M € | +24.2% | 58,8 M € | -19.6% | 73,1 M € | +4.1% | 70,2 M € | +2.0% | 68,9 M € | +85.6% | 37,1 M € | +1.6% | 36,5 M € | +6.5% | 34,3 M € | +6.6% | 32,2 M € | +15.8% | 27,8 M € | +4.2% | 26,7 M € | +0.5% | 26,5 M € | +1.2% | 26,2 M € | +1.9% | 25,7 M € | +6.1% | 24,3 M € | |
| EBITDA | 4,4 M € | +13.2% | 3,9 M € | -24.1% | 5,1 M € | +40.3% | 3,7 M € | +73.8% | 2,1 M € | -29.8% | 3,0 M € | -26.3% | 4,1 M € | +17.0% | 3,5 M € | +85.7% | 1,9 M € | +31.9% | 1,4 M € | +41.6% | 1,0 M € | -12.4% | 1,1 M € | -14.6% | 1,3 M € | +34.6% | 994,0 k € | -19.8% | 1,2 M € | +18.6% | 1,0 M € | -3.1% | 1,1 M € | -14.6% | 1,3 M € | -0.5% | 1,3 M € | |
| Operating profit | 4,3 M € | +14.9% | 3,8 M € | -24.7% | 5,0 M € | +42.0% | 3,5 M € | -20.3% | 4,4 M € | +58.0% | 2,8 M € | -27.5% | 3,9 M € | +18.2% | 3,3 M € | +97.5% | 1,7 M € | +23.1% | 1,3 M € | +45.6% | 921,5 k € | -12.1% | 1,0 M € | -15.8% | 1,2 M € | +38.4% | 899,5 k € | -21.0% | 1,1 M € | +20.1% | 947,6 k € | -2.8% | 975,1 k € | -14.3% | 1,1 M € | +2.2% | 1,1 M € | |
| Profit/loss | 3,3 M € | +5.6% | 3,2 M € | -28.4% | 4,4 M € | +82.0% | 2,4 M € | -26.0% | 3,3 M € | +89.4% | 1,7 M € | -30.7% | 2,5 M € | +16.7% | 2,1 M € | +110.0% | 1,0 M € | +26.3% | 809,4 k € | +44.3% | 560,7 k € | -13.2% | 646,3 k € | -15.5% | 764,9 k € | +37.9% | 554,8 k € | -20.9% | 701,2 k € | +18.9% | 589,9 k € | -5.9% | 626,6 k € | -18.5% | 768,5 k € | +6.2% | 723,9 k € | |
| Equity | 37,0 M € | +9.9% | 33,6 M € | +10.4% | 30,5 M € | +17.0% | 26,0 M € | +10.3% | 23,6 M € | +16.2% | 20,3 M € | +9.3% | 18,6 M € | +15.6% | 16,1 M € | +15.4% | 13,9 M € | +130.5% | 6,0 M € | +15.5% | 5,2 M € | -21.6% | 6,7 M € | +2.2% | 6,5 M € | +13.3% | 5,8 M € | +10.6% | 5,2 M € | +15.6% | 4,5 M € | +15.1% | 3,9 M € | +19.0% | 3,3 M € | +30.5% | 2,5 M € | |
| Total assets | 60,0 M € | +36.1% | 44,1 M € | +4.1% | 42,3 M € | +23.3% | 34,3 M € | -1.2% | 34,8 M € | +16.1% | 29,9 M € | +5.3% | 28,4 M € | +15.4% | 24,7 M € | +4.8% | 23,5 M € | +111.6% | 11,1 M € | -12.4% | 12,7 M € | +5.2% | 12,1 M € | +3.8% | 11,6 M € | +10.8% | 10,5 M € | +5.9% | 9,9 M € | +5.1% | 9,4 M € | +0.5% | 9,4 M € | -7.7% | 10,2 M € | +1.4% | 10,0 M € | |
| Cash | — | — | — | — | — | — | 1,7 M € | +311.7% | 409,0 k € | -26.8% | 558,4 k € | +414.6% | 108,5 k € | +5.6% | 102,8 k € | +1.9% | 100,9 k € | +15.9% | 87,0 k € | +15.7% | 75,2 k € | -4.8% | 79,0 k € | -58.5% | 190,5 k € | +721.0% | 23,2 k € | -32.8% | 34,5 k € | +133.2% | 14,8 k € | |||||||
| Debts | 20,6 M € | +142.5% | 8,5 M € | -14.6% | 10,0 M € | +41.2% | 7,1 M € | -30.2% | 10,1 M € | +57.5% | 6,4 M € | -28.9% | 9,0 M € | +13.0% | 8,0 M € | -7.4% | 8,6 M € | +84.6% | 4,7 M € | -34.6% | 7,2 M € | +40.3% | 5,1 M € | +5.9% | 4,8 M € | +14.7% | 4,2 M € | -4.1% | 4,4 M € | -7.3% | 4,7 M € | -11.0% | 5,3 M € | -19.8% | 6,6 M € | -8.3% | 7,2 M € | |
| Staff | 84,5 | 88,3 | 94,6 | 99,4 | 118,6 | 119,6 | 126,5 | 132,1 | 126,2 | 58,3 | 59,3 | 56,8 | 54,4 | 52,1 | 54,4 | 55,3 | 55,2 | 51,7 | 48,6 | |||||||||||||||||||
Private limited company · Machelen (Brab.) · incorporated on 30/04/2001 · 84,5 ETP
Private limited company profitable and well capitalised. Cash position rising (+311.7%).
Solid counterparty for a standard engagement.
ZIMMER BIOMET is a Private limited company incorporated in 2001. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Machelen (Brab.). It employs on average 84,5 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette